Peter Friedl, theme Cancer development and immunce defense, and colleagues of The University of Texas MD Anderson Cancer Center, have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
The researchers show how the technique can monitor and capture the dynamics of tumor cell interaction with bone and bone resident cells as they occur over time.
- A tissue-engineered construct under a mouse’s skin develops in about a month into bone with an internal cavity and a thin outer layer that the microscope can “see” through.
- After bone marrow and other cells populate the cavity, a cancer cell line is injected.
- Interactions between malignant cells and bone cells are viewed through the multiphoton microscope via a small glass window sewn into the skin above the bone.
Multiphoton microscopy is a fluorescent imaging technique used to image living tissue. The microscopes in the lab of Peter Friedl, can capture up to seven parameters at a time. Friedl is senior author of the study.
The bone construct was developed by a team of scientists at the Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, in Brisbane, Australia, led by Dietmar Hutmacher, Ph.D. Normal bone biology involves a balance between bone-creating cells called osteoblasts, and bone-destroying cells called osteoclasts, Eleonora Dondossola, the first author of the article and senior team member in peter Friedl's laboratory at MD Anderson Cancer Center, notes. Cancer tips this balance, altering the equilibrium between these two populations and leading to symptomatic bone remodeling. The team’s microscopy showed bone loss concentrated around osteoclasts near the tumor. This phenomenon is a known and painful issue for patients with prostate cancer bone metastasis, and a class of drugs called bisphosphonates is used to relieve this symptom. In the clinic, the effect is known to be palliative, relieving pain but not prolonging survival. The team’s multiphoton microscopy captured this effect. They treated the mice with the bisphosphonate zoledronic acid and found that the drug did not reduce the number of osteoclasts, but slowed their activity, preserving bone. Notably, the treatment had no effect on tumor growth, and this explains why the bone is stabilized but patient survival is not prolonged.
Friedl’s lab is using this model to study cancer treatments in mice, including co-clinical work in immunotherapy and radiation. Drugs that free the immune system to attack cancer are often thwarted by resistance factors in the tumor microenvironment, which the team hopes to observe and characterize.
Related news items
H2020 Grant for Frank Walboomers and Ronald Bartels23 May 2019
Frank Walboomers and Ronald Bartels, theme Reconstructive and regenerative medicine, have received a € 500,000 grant for research into graphene biomaterials from the Europan Union Horizon 2020 FET Open programme.read more
Innovation Grant Dutch Kidney Foundation for Jeroen de Baaij23 May 2019
Jeroen de Baaij, theme Renal disorders, was awarded with an Innovation Grant of the Dutch Kidney Foundation. Jeroen's research proposal was selected from a competitive field of innovative approaches to treat kidney disease.read more
Graduate school news Adjusted PhD guidelines23 May 2019
It should be emphasized that the quality, and not the number of chapters, determines the assessment by the manuscript committee. To avoid the wrong emphasis on quantity, it is not recommended to have more than three publishable chapters in the thesis.read more
Stress among PhD candidates23 May 2019
Do you struggle with too much stress at work or with your PhD project and is there a high workload? Are there problems with your supervisor or a colleague that you cannot resolve? Do you miss a balance between work and private life? Then make an appointment with one of our Radboudumc counselors.read more
Secure trial usual care to a restrictive patient selection for gallbladder surgery23 May 2019
In Lancet Kees van Laarhoven and colleagues showed that usual care for gallstone patients is suboptimal and that less than two third of patients are pain-free after surgery.read more